vs
MERIT MEDICAL SYSTEMS INC（MMSI）とRevolve Group, Inc.（RVLV）の財務データ比較。上の社名をクリックして会社を切り替えられます
MERIT MEDICAL SYSTEMS INCの直近四半期売上が大きい（$393.9M vs $324.4M、Revolve Group, Inc.の約1.2倍）。MERIT MEDICAL SYSTEMS INCの純利益率が高く（9.6% vs 5.7%、差は3.9%）。MERIT MEDICAL SYSTEMS INCの前年同期比売上増加率が高い（10.9% vs 10.4%）。MERIT MEDICAL SYSTEMS INCの直近四半期フリーキャッシュフローが多い（$74.0M vs $-13.3M）。過去8四半期でMERIT MEDICAL SYSTEMS INCの売上複合成長率が高い（10.3% vs 9.5%）
メリットメディカルシステムズ社はグローバルな医療機器メーカーで、心臓病学、放射線学、腫瘍学、内視鏡検査、救命救護の各分野で使用される介入・診断用製品を開発・製造・販売しています。世界中の病院や医療機関に低侵襲のソリューションを提供し、患者の予後改善と診療効率の向上を支援しています。
Revolve Theatre Companyはテムズ河畔ヘンリーを拠点とする劇団で、政治的なテーマの作品やシェイクスピア劇を専門に制作・上演しており、オリバー・デンチ、ジョー・モリス、トム・スミスの3人が所有しています。
MMSI vs RVLV — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $393.9M | $324.4M |
| 純利益 | $38.0M | $18.6M |
| 粗利率 | 49.6% | 53.3% |
| 営業利益率 | 13.8% | 6.3% |
| 純利益率 | 9.6% | 5.7% |
| 売上前年比 | 10.9% | 10.4% |
| 純利益前年比 | 36.0% | 50.4% |
| EPS（希薄化後） | $0.64 | $0.27 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $393.9M | $324.4M | ||
| Q3 25 | $384.2M | $295.6M | ||
| Q2 25 | $382.5M | $309.0M | ||
| Q1 25 | $355.4M | $296.7M | ||
| Q4 24 | $355.2M | $293.7M | ||
| Q3 24 | $339.8M | $283.1M | ||
| Q2 24 | $338.0M | $282.5M | ||
| Q1 24 | $323.5M | $270.6M |
| Q4 25 | $38.0M | $18.6M | ||
| Q3 25 | $27.8M | $21.2M | ||
| Q2 25 | $32.6M | $10.2M | ||
| Q1 25 | $30.1M | $11.8M | ||
| Q4 24 | $27.9M | $12.3M | ||
| Q3 24 | $28.4M | $11.0M | ||
| Q2 24 | $35.7M | $15.4M | ||
| Q1 24 | $28.2M | $10.9M |
| Q4 25 | 49.6% | 53.3% | ||
| Q3 25 | 48.5% | 54.6% | ||
| Q2 25 | 48.2% | 54.1% | ||
| Q1 25 | 48.4% | 52.0% | ||
| Q4 24 | 48.7% | 52.5% | ||
| Q3 24 | 46.4% | 51.2% | ||
| Q2 24 | 47.7% | 54.0% | ||
| Q1 24 | 46.9% | 52.3% |
| Q4 25 | 13.8% | 6.3% | ||
| Q3 25 | 11.1% | 7.1% | ||
| Q2 25 | 12.3% | 5.8% | ||
| Q1 25 | 11.5% | 5.0% | ||
| Q4 24 | 10.3% | 3.9% | ||
| Q3 24 | 11.0% | 5.0% | ||
| Q2 24 | 13.6% | 5.8% | ||
| Q1 24 | 11.1% | 3.4% |
| Q4 25 | 9.6% | 5.7% | ||
| Q3 25 | 7.2% | 7.2% | ||
| Q2 25 | 8.5% | 3.3% | ||
| Q1 25 | 8.5% | 4.0% | ||
| Q4 24 | 7.9% | 4.2% | ||
| Q3 24 | 8.4% | 3.9% | ||
| Q2 24 | 10.6% | 5.4% | ||
| Q1 24 | 8.7% | 4.0% |
| Q4 25 | $0.64 | $0.27 | ||
| Q3 25 | $0.46 | $0.29 | ||
| Q2 25 | $0.54 | $0.14 | ||
| Q1 25 | $0.49 | $0.16 | ||
| Q4 24 | $0.46 | $0.18 | ||
| Q3 24 | $0.48 | $0.15 | ||
| Q2 24 | $0.61 | $0.21 | ||
| Q1 24 | $0.48 | $0.15 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $446.4M | $292.3M |
| 総負債低いほど良い | $734.0M | — |
| 株主資本純資産 | $1.6B | $512.5M |
| 総資産 | $2.7B | $765.0M |
| 負債/資本比率低いほどレバレッジが低い | 0.46× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $446.4M | $292.3M | ||
| Q3 25 | $392.5M | $315.4M | ||
| Q2 25 | $341.8M | $310.7M | ||
| Q1 25 | $395.5M | $300.8M | ||
| Q4 24 | $376.7M | $256.6M | ||
| Q3 24 | $523.1M | $252.8M | ||
| Q2 24 | $636.7M | $244.7M | ||
| Q1 24 | $581.9M | $273.4M |
| Q4 25 | $734.0M | — | ||
| Q3 25 | $732.9M | — | ||
| Q2 25 | $731.8M | — | ||
| Q1 25 | $730.7M | — | ||
| Q4 24 | $729.6M | — | ||
| Q3 24 | $750.5M | — | ||
| Q2 24 | $801.3M | — | ||
| Q1 24 | $800.1M | — |
| Q4 25 | $1.6B | $512.5M | ||
| Q3 25 | $1.5B | $490.2M | ||
| Q2 25 | $1.5B | $468.6M | ||
| Q1 25 | $1.4B | $453.4M | ||
| Q4 24 | $1.4B | $437.8M | ||
| Q3 24 | $1.3B | $420.8M | ||
| Q2 24 | $1.3B | $405.8M | ||
| Q1 24 | $1.2B | $389.9M |
| Q4 25 | $2.7B | $765.0M | ||
| Q3 25 | $2.6B | $751.3M | ||
| Q2 25 | $2.6B | $722.9M | ||
| Q1 25 | $2.5B | $713.9M | ||
| Q4 24 | $2.4B | $665.5M | ||
| Q3 24 | $2.4B | $670.9M | ||
| Q2 24 | $2.4B | $657.8M | ||
| Q1 24 | $2.3B | $650.0M |
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.49× | — | ||
| Q1 25 | 0.51× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.57× | — | ||
| Q2 24 | 0.62× | — | ||
| Q1 24 | 0.65× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $98.5M | $-10.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $74.0M | $-13.3M |
| FCFマージンFCF / 売上 | 18.8% | -4.1% |
| 設備投資強度設備投資 / 売上 | 6.2% | 1.0% |
| キャッシュ転換率営業CF / 純利益 | 2.59× | -0.55× |
| 直近12ヶ月FCF直近4四半期 | $215.7M | $48.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $98.5M | $-10.2M | ||
| Q3 25 | $75.0M | $11.8M | ||
| Q2 25 | $83.3M | $12.6M | ||
| Q1 25 | $40.6M | $45.1M | ||
| Q4 24 | $68.7M | $3.9M | ||
| Q3 24 | $47.3M | $9.1M | ||
| Q2 24 | $68.5M | $-24.7M | ||
| Q1 24 | $36.2M | $38.4M |
| Q4 25 | $74.0M | $-13.3M | ||
| Q3 25 | $52.5M | $7.5M | ||
| Q2 25 | $69.6M | $10.4M | ||
| Q1 25 | $19.5M | $43.4M | ||
| Q4 24 | $65.3M | $2.1M | ||
| Q3 24 | $38.0M | $8.0M | ||
| Q2 24 | $57.9M | $-25.7M | ||
| Q1 24 | $24.5M | $36.7M |
| Q4 25 | 18.8% | -4.1% | ||
| Q3 25 | 13.7% | 2.5% | ||
| Q2 25 | 18.2% | 3.4% | ||
| Q1 25 | 5.5% | 14.6% | ||
| Q4 24 | 18.4% | 0.7% | ||
| Q3 24 | 11.2% | 2.8% | ||
| Q2 24 | 17.1% | -9.1% | ||
| Q1 24 | 7.6% | 13.5% |
| Q4 25 | 6.2% | 1.0% | ||
| Q3 25 | 5.8% | 1.5% | ||
| Q2 25 | 3.6% | 0.7% | ||
| Q1 25 | 5.9% | 0.6% | ||
| Q4 24 | 1.0% | 0.6% | ||
| Q3 24 | 2.8% | 0.4% | ||
| Q2 24 | 3.1% | 0.4% | ||
| Q1 24 | 3.6% | 0.6% |
| Q4 25 | 2.59× | -0.55× | ||
| Q3 25 | 2.70× | 0.56× | ||
| Q2 25 | 2.56× | 1.24× | ||
| Q1 25 | 1.35× | 3.82× | ||
| Q4 24 | 2.46× | 0.32× | ||
| Q3 24 | 1.66× | 0.83× | ||
| Q2 24 | 1.92× | -1.60× | ||
| Q1 24 | 1.28× | 3.53× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MMSI
| Other | $154.6M | 39% |
| Peripheral Intervention | $93.2M | 24% |
| Cardiac Intervention | $50.2M | 13% |
| OEM | $42.6M | 11% |
| Custom Procedural Solutions | $33.1M | 8% |
| Endoscopy Segment | $20.1M | 5% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
